Overview of the interactive map interface
You can explore two different views on the interactive map:
- A pin map provides an overview of individual clinical trials, implementation studies and national or regional LDCT screening programmes.
- A heat map displays the policy context for LDCT screening of lung cancer in each country.
Additional information on what is known about each study/programme or country can be viewed in a summary table or ‘dashboard’ that displays either to the left of the map or under it, depending on whether you are using a desktop or mobile.
For more information about how the data set was built for this map, click the button below to read the interactive map methodology.
Key features of the map interface
You can explore the interactive map in a variety of ways, depending on the type of information that most interests you. For both maps, you can:
- Browse by location: click on the ‘quick start’ menu to zoom in to different areas of the map at the country or city level.
- Explore individual entries or countries: click a pin or the outline of a country on the heat map to view more information.
- Refine your search: filters in the navigation bar can be selected to reduce the number of pins or countries that appear on the map.
- Search for something specific: as you start typing into the search bar, it will filter the results for you in real time.
- Compare data: a comparison tool enables the side-by-side display of variables for the studies/programmes or countries selected.
- Share the data: you can easily share a direct link to an entry on the pin map or heat map using the ‘Share link to entry’ button or the ‘Tweet this entry’ button. Data from the comparison tool can also be downloaded as a PDF.
A virtual tour is available to guide users on how to interact with the map interface. This should appear automatically, but if not, it can be accessed by clicking the button at the bottom of either map.
Definitions applied to the interactive map interface
The full data set contains more than 50 variables. All of the definitions for the variables used to build the interactive map are included in the full methodology and the cover sheet for the CSV database download.
Click here to download the full data set.
Outlined below are explanations for a small number of these variables, which we hope will support you in engaging with the data set.
Throughout the interactive map, a dash (‘–’) indicates missing data and ‘N/A’ means that a variable does not apply.
For other definitions around lung cancer screening, please click the button below to visit the glossary.
|Acronym||The acronym used to abbreviate the full name of the study/programme for this map – including official acronyms (if an official acronym cannot be identified, one will be drafted to optimise the user experience of the map interface)|
|Design||Whether the entry is a clinical trial, implementation study or national/regional programme (see glossary)|
|Status||Whether the study/programme is ongoing (active) or complete (inactive)|
|# sites in country||If the study/programme is an international multicentre initiative, the number of sites within this country|
|Screening interval||The frequency of screening offered to participants at baseline or prior to enrolment (e.g. annual scan)|
|Radiation dose reported||Whether information on the level of radiation emitted by a single LDCT scan is available in the literature (yes, no)|
|# targeted participants||The number of participants that the study/programme seeks to enrol|
|# participants screened to date||The total number of participants last reported to have undergone LDCT screening so far|
|Additional research focus||e.g. Workforce capacity, Barriers to screening, Cost-effectiveness, Eligibility criteria|
|Age range: yearsa||The minimum and maximum age considered eligible for screening
|Smoking history: PYsa||The minimum smoking history, in number of pack-years (PYs), an individual is required to have to participate in screening (e.g. ≥30)|
|Smoking history: YSQa||The minimum number of years since quitting smoking (YSQ) required for an individual to participate in screening (e.g. ≤15)|
|Never smokers eligible||Whether people who have never smoked are eligible to participate in screening|
|Other risk factors||The number of other risk factors considered when assessing whether an individual is eligible for screening, such as exposure to asbestos or a family history of lung cancer (e.g. 2)|
|Screening uptake (%)b||The proportion of the target population that responded to an invitation for screening and attended for an LDCT baseline scan|
|Confirmed lung cancer cases (%)b||The proportion of participants who underwent baseline LDCT screening and were reported to have a true positive (confirmed) result for lung cancer|
|Stage I/II lung cancer cases (%)b||The proportion of participants in whom lung cancer was detected and diagnosed at stage I/II|
a If there is any variation in age and smoking history based on other risk factors for lung cancer, this will be indicated by an asterisk and footnote.
b Proportions expressed as percentages (%)
|Lung cancer incidence||The number of lung cancer cases per 100,000 population from the GLOBOCAN 2020 data set (global age-standardised rate, including sex-specific rates)1|
|Lung cancer mortality||The number of lung cancer deaths per 100,000 population from the GLOBOCAN 2020 data set (global age-standardised rate, including sex-specific rates)1|
|National cancer control plan (NCCP)||Whether there is an NCCP available (and, if so, the year the last NCCP was published) and whether it discussed a strategy for the early detection of lung cancer|
|Population-based cancer registry (PBCR)||Whether there is a population-based cancer registry that captures cancer incidence/mortality in a given country|
|Country status||Only the latest ‘stage’ that a country has reached along the lung cancer screening implementation pathway will be shown.
• Unknown status: Either no data could be identified from the literature search or there are clinical trials or studies related to LDCT lung cancer screening, but no formal position on lung cancer screening at the national level is known.
• Implementation research: The country has previously or is currently conducting small-scale regional or national implementation studies, including pilot programmes.
• Formal commitment to implement: The country has formally committed to the implementation of LDCT lung cancer screening in its national cancer control plan or in other official legislation/notices.
• Implementation roll-out: An organised LDCT screening programme is being rolled out or has previously been rolled out to the entire eligible population, either within a certain region of the country or nationwide.